A citation-based method for searching scientific literature

Carol Aghajanian, Stephanie V Blank, Barbara A Goff, Patricia L Judson, Michael G Teneriello, Amreen Husain, Mika A Sovak, Jing Yi, Lawrence R Nycum. J Clin Oncol 2012
Times Cited: 776







List of co-cited articles
538 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


PARP inhibitors in ovarian cancer.
Elisena Franzese, Sara Centonze, Anna Diana, Francesca Carlino, Luigi Pio Guerrera, Marilena Di Napoli, Ferdinando De Vita, Sandro Pignata, Fortunato Ciardiello, Michele Orditura. Cancer Treat Rev 2019
78
5

Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial.
Michael Friedlander, Val Gebski, Emma Gibbs, Lucy Davies, Ralph Bloomfield, Felix Hilpert, Lari B Wenzel, Daniel Eek, Manuel Rodrigues, Andrew Clamp,[...]. Lancet Oncol 2018
69
5

Integrated genomic characterization of endometrial carcinoma.
Cyriac Kandoth, Nikolaus Schultz, Andrew D Cherniack, Rehan Akbani, Yuexin Liu, Hui Shen, A Gordon Robertson, Itai Pashtan, Ronglai Shen, Christopher C Benz,[...]. Nature 2013
4

Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.
Richard W Tothill, Anna V Tinker, Joshy George, Robert Brown, Stephen B Fox, Stephen Lade, Daryl S Johnson, Melanie K Trivett, Dariush Etemadmoghadam, Bianca Locandro,[...]. Clin Cancer Res 2008
899
4

Safety and dose modification for patients receiving niraparib.
J S Berek, U A Matulonis, U Peen, P Ghatage, S Mahner, A Redondo, A Lesoin, N Colombo, I Vergote, O Rosengarten,[...]. Ann Oncol 2018
65
6

Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes.
Darren R Hodgson, Brian A Dougherty, Zhongwu Lai, Anitra Fielding, Lynda Grinsted, Stuart Spencer, Mark J O'Connor, Tony W Ho, Jane D Robertson, Jerry S Lanchbury,[...]. Br J Cancer 2018
67
5

Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG).
Gordon John Sampson Rustin, Ignace Vergote, Elizabeth Eisenhauer, Eric Pujade-Lauraine, Michael Quinn, Tate Thigpen, Andreas du Bois, Gunnar Kristensen, Anders Jakobsen, Satoru Sagae,[...]. Int J Gynecol Cancer 2011
349
4

Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.
Kathryn P Pennington, Tom Walsh, Maria I Harrell, Ming K Lee, Christopher C Pennil, Mara H Rendi, Anne Thornton, Barbara M Norquist, Silvia Casadei, Alexander S Nord,[...]. Clin Cancer Res 2014
489
4

Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer.
J P Neijt, S A Engelholm, M K Tuxen, P G Sorensen, M Hansen, C Sessa, C A de Swart, F R Hirsch, B Lund, H C van Houwelingen. J Clin Oncol 2000
331
4

Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety.
U A Matulonis, R T Penson, S M Domchek, B Kaufman, R Shapira-Frommer, M W Audeh, S Kaye, L R Molife, K A Gelmon, J D Robertson,[...]. Ann Oncol 2016
83
4

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.
Hannah Farmer, Nuala McCabe, Christopher J Lord, Andrew N J Tutt, Damian A Johnson, Tobias B Richardson, Manuela Santarosa, Krystyna J Dillon, Ian Hickson, Charlotte Knights,[...]. Nature 2005
4

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.
Fairooz Kabbinavar, Herbert I Hurwitz, Louis Fehrenbacher, Neal J Meropol, William F Novotny, Grazyna Lieberman, Susan Griffing, Emily Bergsland. J Clin Oncol 2003
4

Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Radoslav Chekerov, Felix Hilpert, Sven Mahner, Ahmed El-Balat, Philipp Harter, Nikolaus De Gregorio, Claudius Fridrich, Susanne Markmann, Jochem Potenberg, Ralf Lorenz,[...]. Lancet Oncol 2018
35
11

Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study.
Jung-Min Lee, Ashley Cimino-Mathews, Cody J Peer, Alexandra Zimmer, Stanley Lipkowitz, Christina M Annunziata, Liang Cao, Maria I Harrell, Elizabeth M Swisher, Nicole Houston,[...]. J Clin Oncol 2017
135
4

Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial.
Joyce F Liu, Christina Herold, Kathryn P Gray, Richard T Penson, Neil Horowitz, Panagiotis A Konstantinopoulos, Cesar M Castro, Sarah J Hill, Jennifer Curtis, Weixiu Luo,[...]. JAMA Oncol 2019
50
8

Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51.
Alanna R Kaplan, Susan E Gueble, Yanfeng Liu, Sebastian Oeck, Hoon Kim, Zhong Yun, Peter M Glazer. Sci Transl Med 2019
52
7

Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.
Amit M Oza, Anna V Tinker, Ana Oaknin, Ronnie Shapira-Frommer, Iain A McNeish, Elizabeth M Swisher, Isabelle Ray-Coquard, Katherine Bell-McGuinn, Robert L Coleman, David M O'Malley,[...]. Gynecol Oncol 2017
126
4

Bevacizumab combined with platinum-taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial).
Shinichi Komiyama, Kazuyoshi Kato, Yuki Inokuchi, Hirokuni Takano, Takashi Matsumoto, Atsushi Hongo, Mikiko Asai-Sato, Atsushi Arakawa, Shoji Kamiura, Tsutomu Tabata,[...]. Int J Clin Oncol 2019
23
17

A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms.
Philipp Harter, Jalid Sehouli, Domenica Lorusso, Alexander Reuss, Ignace Vergote, Christian Marth, Jae-Weon Kim, Francesco Raspagliesi, Björn Lampe, Giovanni Aletti,[...]. N Engl J Med 2019
143
4


Cancer statistics, 2020.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2020
4

Whole-genome characterization of chemoresistant ovarian cancer.
Ann-Marie Patch, Elizabeth L Christie, Dariush Etemadmoghadam, Dale W Garsed, Joshy George, Sian Fereday, Katia Nones, Prue Cowin, Kathryn Alsop, Peter J Bailey,[...]. Nature 2015
728
4

Combinations of Bevacizumab With Cancer Immunotherapy.
Daniel S Chen, Herbert Hurwitz. Cancer J 2018
66
6

Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer.
Antonio González Martín, Amit M Oza, Andrew C Embleton, Jacobus Pfisterer, Jonathan A Ledermann, Eric Pujade-Lauraine, Gunnar Kristensen, Monique A Bertrand, Philip Beale, Andrés Cervantes,[...]. Gynecol Oncol 2019
21
19

Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018.
J Ferlay, M Colombet, I Soerjomataram, T Dyba, G Randi, M Bettio, A Gavin, O Visser, F Bray. Eur J Cancer 2018
812
3

Exploring and comparing adverse events between PARP inhibitors.
Christopher J LaFargue, Graziela Z Dal Molin, Anil K Sood, Robert L Coleman. Lancet Oncol 2019
89
3

Management of platinum-sensitive recurrent ovarian cancer.
Jacobus Pfisterer, Jonathan A Ledermann. Semin Oncol 2006
81
3

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.
Helen E Bryant, Niklas Schultz, Huw D Thomas, Kayan M Parker, Dan Flower, Elena Lopez, Suzanne Kyle, Mark Meuth, Nicola J Curtin, Thomas Helleday. Nature 2005
3

Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer.
A P M Heintz, F Odicino, P Maisonneuve, M A Quinn, J L Benedet, W T Creasman, H Y S Ngan, S Pecorelli, U Beller. Int J Gynaecol Obstet 2006
506
3

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial.
Markus M Heiss, Pawel Murawa, Piotr Koralewski, Elzbieta Kutarska, Olena O Kolesnik, Vladimir V Ivanchenko, Alexander S Dudnichenko, Birute Aleknaviciene, Arturas Razbadauskas, Martin Gore,[...]. Int J Cancer 2010
297
3

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival.
Bernard Escudier, Joaquim Bellmunt, Sylvie Négrier, Emilio Bajetta, Bohuslav Melichar, Sergio Bracarda, Alain Ravaud, Sophie Golding, Sangeeta Jethwa, Vesna Sneller. J Clin Oncol 2010
576
3

Tumor angiogenesis.
Robert S Kerbel. N Engl J Med 2008
3

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.
Henry S Friedman, Michael D Prados, Patrick Y Wen, Tom Mikkelsen, David Schiff, Lauren E Abrey, W K Alfred Yung, Nina Paleologos, Martin K Nicholas, Randy Jensen,[...]. J Clin Oncol 2009
3

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.
Brian I Rini, Susan Halabi, Jonathan E Rosenberg, Walter M Stadler, Daniel A Vaena, San-San Ou, Laura Archer, James N Atkins, Joel Picus, Piotr Czaykowski,[...]. J Clin Oncol 2008
694
3


Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy.
Yong Fang, Daniel J McGrail, Chaoyang Sun, Marilyne Labrie, Xiaohua Chen, Dong Zhang, Zhenlin Ju, Christopher P Vellano, Yiling Lu, Yongsheng Li,[...]. Cancer Cell 2019
64
4

Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer.
Jonathan A Ledermann, Eric Pujade-Lauraine. Ther Adv Med Oncol 2019
37
8

PARP inhibitors in ovarian cancer.
J A Ledermann. Ann Oncol 2016
73
4

PARP Inhibitors in Ovarian Cancer.
Gloria Mittica, Eleonora Ghisoni, Gaia Giannone, Sofia Genta, Massimo Aglietta, Anna Sapino, Giorgio Valabrega. Recent Pat Anticancer Drug Discov 2018
43
6

PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression.
Shiping Jiao, Weiya Xia, Hirohito Yamaguchi, Yongkun Wei, Mei-Kuang Chen, Jung-Mao Hsu, Jennifer L Hsu, Wen-Hsuan Yu, Yi Du, Heng-Huan Lee,[...]. Clin Cancer Res 2017
357
3

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.
Peter C Fong, Timothy A Yap, David S Boss, Craig P Carden, Marja Mergui-Roelvink, Charlie Gourley, Jacques De Greve, Jan Lubinski, Susan Shanley, Christina Messiou,[...]. J Clin Oncol 2010
635
3

ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer.
Christian Marth, Ignace Vergote, Giovanni Scambia, Willi Oberaigner, Andrew Clamp, Regina Berger, Christian Kurzeder, Nicoletta Colombo, Peter Vuylsteke, Domenica Lorusso,[...]. Eur J Cancer 2017
43
6

A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors.
Philippe L Bedard, Josep Tabernero, Filip Janku, Zev A Wainberg, Luis Paz-Ares, Johan Vansteenkiste, Eric Van Cutsem, José Pérez-García, Anastasios Stathis, Carolyn D Britten,[...]. Clin Cancer Res 2015
184
3

Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis.
Lucio Tentori, Pedro Miguel Lacal, Alessia Muzi, Annalisa Susanna Dorio, Carlo Leonetti, Marco Scarsella, Federica Ruffini, Weizheng Xu, Wokee Min, Antonella Stoppacciaro,[...]. Eur J Cancer 2007
102
3

Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma.
John P Diaz, William P Tew, Oliver Zivanovic, Jason Konner, Paul J Sabbatini, Lisa A dos Santos, Nadeem R Abu-Rustum, Dennis S Chi, Carol Aghajanian, Richard R Barakat. Gynecol Oncol 2010
32
9

Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer.
Martin R Stockler, Felix Hilpert, Michael Friedlander, Madeleine T King, Lari Wenzel, Chee Khoon Lee, Florence Joly, Nikolaus de Gregorio, José Angel Arranz, Mansoor Raza Mirza,[...]. J Clin Oncol 2014
109
3

The combination of circulating Ang1 and Tie2 levels predicts progression-free survival advantage in bevacizumab-treated patients with ovarian cancer.
Alison Backen, Andrew G Renehan, Andrew R Clamp, Carlo Berzuini, Cong Zhou, Amit Oza, Selina Bannoo, Stefan J Scherer, Rosamonde E Banks, Caroline Dive,[...]. Clin Cancer Res 2014
46
6

Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.
Gunter von Minckwitz, Fabio Puglisi, Javier Cortes, Eduard Vrdoljak, Norbert Marschner, Christoph Zielinski, Cristian Villanueva, Gilles Romieu, István Lang, Eva Ciruelos,[...]. Lancet Oncol 2014
90
3

Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study.
Barbara M Norquist, Mark F Brady, Maria I Harrell, Tom Walsh, Ming K Lee, Suleyman Gulsuner, Sarah S Bernards, Silvia Casadei, Robert A Burger, Krishnansu S Tewari,[...]. Clin Cancer Res 2018
80
3



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.